false
0001788028
0001788028
2026-11-16
2026-11-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
November 16, 2026
JASPER THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in its
Charter)
| Delaware |
|
001-39138 |
|
84-2984849 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
2200 Bridge Pkwy Suite #102
Redwood City, California 94065
(Address of Principal Executive Offices) (Zip
Code)
(650) 549-1400
Registrant’s telephone number, including
area code
N/A
(Former Name, or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Exchange Act:
| (Title of each class) |
|
(Trading Symbol) |
|
(Name of exchange on which registered) |
| Voting Common Stock, par value $0.0001 per share |
|
JSPR |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On November 16, 2026, Jasper Therapeutics, Inc.
issued a press release reporting its financial results for the quarter ended September 30, 2026 and providing a corporate update. A copy
of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
In accordance with General Instructions B.2 of
Form 8-K, the information in this Item 2.02, including the press release attached hereto as Exhibit 99.1, is being furnished under Item
2.02 and Item 9.01 of Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not
be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be
expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. |
|
Description |
| 99.1 |
|
Press Release, dated November 16, 2026. |
| 104 |
|
Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL). |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: November 16, 2026 |
JASPER THERAPEUTICS, INC. |
| |
|
| |
By: |
/s/ Jeet Mahal |
| |
Name: |
Jeet Mahal |
| |
Title: |
Chief Executive Officer |
Exhibit 99.1

Jasper
Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
REDWOOD
CITY, Calif., November 16, 2026 (GLOBE NEWSWIRE) – Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical
stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today reported
results for the fiscal quarter ended September 30, 2026, and provided a corporate update.
“We
have made progress advancing our development programs in recent months following our acquisition of Kira Pharmaceuticals, highlighted
by the recent completion of enrollment in the first cohort of our Phase 2 renal basket study evaluating vensobafusp alfa (KP104) in patients
with IgA nephropathy (IgAN),” said Jeet Mahal, President and Chief Executive Officer of Jasper. “In addition, we enrolled
the first patient with immune complex membranoproliferative glomerulonephritis (IC-MPGN) in the renal basket study and commenced an expansion
cohort in patients with focal segmental glomerulosclerosis (FSGS), with the first patient expected to be dosed in the first quarter of
2027. We believe that the bifunctional ability of vensobafusp alfa to inhibit both the alternative and terminal complement pathways may
provide the potential for differentiated onset and efficacy in complement driven diseases, and we look forward to presenting interim
data from the IgAN cohort in the fourth quarter of 2026 and additional updates from our pipeline programs in 2027.”
Third
Quarter 2026 and Recent Highlights
| ● | Completed
enrollment in first cohort of Phase 2 renal basket study evaluating vensobafusp alfa in IgA
nephropathy. |
| ○ | Jasper
expects to report interim IgAN data from Stage 1 of the renal basket study in the fourth
quarter of 2026 and updated data in the first quarter of 2027. |
| ● | Announced
the opening of an expansion cohort in the renal basket study evaluating vensobafusp alfa
in patients with FSGS, with first patients expected to be dosed in first quarter 2027. |
| ● | Commenced
patient enrollment in the C3 glomerulopathy (C3G)/IC-MPGN cohort of the renal basket study.
|
| ○ | First
IC-MPGN patient dosed. |
| ○ | IC-MPGN
is a complement-mediated glomerulonephritis characterized by immune complex deposition, complement
activation, and downstream alternative pathway amplification. Given the overlap with C3G
in complement biology, IC-MPGN is being evaluated together with C3G in a rare complement-mediated
kidney disease cohort |
| ● | Jasper
is completing a Phase 1/2 case control study evaluating briquilimab as a conditioning agent
for SCID patients receiving hematopoietic stem cell transplant. |
| ○ | The
company expects to present initial data from the study in the fourth quarter of 2026. |
| ● | In
July 2026, Jasper completed the acquisition of Kira Pharmaceuticals (“Kira”),
a Cayman limited company that was engaged in the design of complement therapies to treat
immune-mediated diseases, in an all-stock transaction. |
| ○ | Concurrently
with the acquisition, Jasper entered into a securities purchase agreement for the sale of
non-voting convertible preferred stock (the “Preferred Stock”) in a private placement
co-led by Affinity Asset Advisors, LLC and Ikarian Capital LLC with participation from other
life science investors. The private placement closed on July 20, 2026 and resulted in gross
proceeds of approximately $132.0 million. |
| ● | Announced
the appointment of Lisa Pitt, Pharm.D., M.S.J. as Senior Vice President, Regulatory Affairs
and Shiguang Liu, M.D., Ph.D. as Vice President, Clinical Development. |
| ● | Commenced
an offer to purchase any and all of its outstanding warrants that were issued in its underwritten
public offering on September 18, 2025. The purchase price was $9.72 in cash per warrant (post-reverse
stock split). |
| ○ | The
Company has been advised that a total of 283,689 Warrants (post-reverse stock split) were properly tendered, which represents an aggregate
cash payment of approximately $2.8 million. Following completion of the offer, 127,834 Warrants remain outstanding. |
| ● | In
November 2026, Jasper effected a 1-for-30 reverse stock split (“Reverse Split”)
of the Company’s common stock. Following the Reverse Split, there were approximately
1.1m shares of common stock issued and outstanding. |
Third
Quarter Fiscal 2026 Financial Results
| ● | Cash
and cash equivalents as of September 30, 2026, totaled $135.3 million. |
| ● | Research
and development expense for the three months ended September 30, 2026, was $8.3 million. |
| ● | General
and administrative expense for the three months ended September 30, 2026, was $6.4 million. |
About
Jasper
Jasper
is a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases.
The company is advancing a pipeline of medicines including vensobafusp alfa, briquilimab, and KP701. Vensobafusp alfa is a potential
best-in-class dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under
evaluation in other high unmet need nephrology disorders. Briquilimab is an anti-KIT antibody which has demonstrated positive clinical
results both as a conditioning agent for stem cell transplant in severe combined immunodeficiencies (SCID), Fanconi anemia, as well as
mast cell mediated diseases such as the chronic urticarias. KP701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for
autoantibody-mediated disorders currently advancing to the clinic.
Forward-Looking
Statements
Certain
statements contained in this press release are or may be considered “forward-looking statements” as defined in the Private
Securities Litigation Reform Act of 1995. These statements can be identified by the fact that they do not relate strictly to historic
or current facts. They use words such as “estimate,” “expect,” “intend,” “believe,” “plan,”
“anticipate,” “potential,” “projected” and other words and terms of similar meaning in connection
with any discussion of future operating or financial performance or condition. Jasper cautions that these statements are based upon the
current beliefs and expectations of Jasper’s management and are subject to significant risks, uncertainties and assumptions, including,
without limitation, risks related to the market price of Jasper’s common stock relative to the value suggested by the exchange
ratio in connection with the merger; unexpected costs, charges or expenses resulting from the merger; potential adverse reactions or
changes to business relationships resulting from the completion of the acquisition of Kira; the uncertainties associated with Jasper’s
product candidates, as well as risks associated with the clinical development and regulatory approval of product candidates, including
potential delays in the commencement, enrollment and completion of clinical trials and the timing of data readouts; risks related to
the inability of Jasper to obtain sufficient additional capital to continue to advance product candidates and its preclinical programs;
uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; risks related
to the failure to realize any value from product candidates and preclinical programs being developed and anticipated to be developed
in light of inherent risks and difficulties involved in successfully bringing product candidates to market; risks associated with the
possible failure to realize certain anticipated benefits of the acquisition of Kira, including with respect to future financial and operating
results; risks related to the integration of Kira and realization of anticipated benefits from the combination; risks related to the
possibility that Jasper’s stockholders may not approve the conversion of the preferred stock and the consequences if such approval
is not obtained, including potential obligations to settle preferred stock in cash; Jasper’s ability to maintain the listing of
its common stock on the Nasdaq Capital Market; and such additional risks and uncertainties contained in the “Risk Factors”
section of Jasper’s Annual Report on Form 10-K for the year ended December 31, 2025, its Quarterly Report on Form 10-Q for the
quarter ended September 30, 2026, and other Quarterly Reports on Form 10-Q and Current Reports on Form 8-K that Jasper has subsequently
filed or may subsequently file with the SEC. Statements regarding future actions, future performance and/or future results including,
without limitation, those relating to the timing for completion, and results of, scheduled or additional clinical trials and the FDA’s
or other regulatory review and/or approval and commercial launch and sales results (if any) of Jasper’s formulations and product
candidates and regulatory filings related to the same, financial projections and targets, including, without limitation, cash runway,
operating plans, future capital requirements and the sufficiency of existing cash resources, business strategy, plans and objectives
for future operations, statements regarding Jasper and its operations and prospects, may not occur, and actual results could differ materially
and adversely from those anticipated or implied in the forward-looking statements. In light of these risks, uncertainties and assumptions,
the forward-looking events and circumstances discussed in this press release are inherently uncertain and may not occur, and actual results
could differ materially and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not
rely upon forward-looking statements as predictions of future events. There is no obligation to update publicly or revise any forward-looking
statements for any reason after the date of this press release or to conform these statements to actual results or to changes in Jasper’s
expectations, whether as a result of new information, future events, inaccuracies that become apparent after the date hereof or otherwise,
except as may be required under applicable securities laws.
Contacts:
Alex
Gray (investors)
Jasper Therapeutics
650-549-1454
agray@jaspertx.com
Argot
Partners (investors and media)
kira@argotpartners.com
JASPER THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE LOSS
(in thousands, except share and per share
data)
(unaudited)
| | |
Three Months Ended | | |
Nine Months Ended | |
| | |
September 30, | | |
September 30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| Revenue | |
$ | 8,000 | | |
$ | — | | |
$ | 8,000 | | |
$ | — | |
| Costs and Expenses | |
| | | |
| | | |
| | | |
| | |
| Costs of drug supplies and compounds | |
| 7,993 | | |
| — | | |
| 7,993 | | |
| — | |
| Research and development | |
| 8,327 | | |
| 14,391 | | |
| 19,276 | | |
| 51,744 | |
| General and administrative | |
| 6,359 | | |
| 4,775 | | |
| 15,569 | | |
| 16,300 | |
| Acquired in-process research and development | |
| 129,494 | | |
| — | | |
| 129,494 | | |
| — | |
| Total operating expenses | |
| 152,173 | | |
| 19,166 | | |
| 172,332 | | |
| 68,044 | |
| Loss from operations | |
| (144,173 | ) | |
| (19,166 | ) | |
| (164,332 | ) | |
| (68,044 | ) |
| Interest income | |
| 999 | | |
| 342 | | |
| 1,245 | | |
| 1,403 | |
| Change in fair value of warrant liability | |
| (1,240 | ) | |
| 2,099 | | |
| 12,380 | | |
| 2,099 | |
| Other income (expense), net | |
| (41 | ) | |
| (2,011 | ) | |
| 2,318 | | |
| (2,158 | ) |
| Total other income (expense), net | |
| (282 | ) | |
| 430 | | |
| 15,943 | | |
| 1,344 | |
| Net loss and comprehensive loss | |
$ | (144,455 | ) | |
$ | (18,736 | ) | |
$ | (148,389 | ) | |
$ | (66,700 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Net loss per share attributable to common stockholders, basic and diluted | |
$ | (10.19 | ) | |
$ | (32.08 | ) | |
$ | (14.31 | ) | |
$ | (125.30 | ) |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted | |
| 1,075,259 | | |
| 584,056 | | |
| 1,040,513 | | |
| 532,312 | |
| Net loss per share attributable to non-voting redeemable convertible preferred stockholders, basic and diluted | |
$ | (13.97 | ) | |
$ | — | | |
$ | (13.97 | ) | |
$ | — | |
| Weighted-average shares used in computing net loss per share attributable to non-voting redeemable convertible preferred stockholders, basic and diluted | |
| 9,555,390 | | |
| - | | |
| 9,555,390 | | |
| - | |
(1) Amounts include non-cash stock based compensation expense as follows
(in thousands):
| | |
Three Months Ended
September 30, | | |
Nine Months Ended
September 30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| | |
| | |
| | |
| | |
| |
| Research and development | |
$ | 604 | | |
$ | 486 | | |
$ | 1,010 | | |
$ | 1,600 | |
| General and administrative | |
| 615 | | |
| 938 | | |
| 1,396 | | |
| 3,452 | |
| Total | |
$ | 1,219 | | |
$ | 1,424 | | |
$ | 2,406 | | |
$ | 5,052 | |
JASPER THERAPEUTICS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
(unaudited)
| | |
September 30, | | |
December 31, | |
| Assets | |
2026 | | |
2025 | |
| Current assets: | |
| | |
| |
| Cash and cash equivalents | |
$ | 135,349 | | |
$ | 28,692 | |
| Restricted cash, current | |
| 417 | | |
| - | |
| Accounts receivable | |
| 8,000 | | |
| - | |
| Prepaid expenses and other current assets | |
| 3,508 | | |
| 5,953 | |
| Total current assets | |
| 147,274 | | |
| 34,645 | |
| Property and equipment, net | |
| 57 | | |
| 102 | |
| Operating lease right-of-use assets | |
| 67 | | |
| 502 | |
| Restricted cash, non-current | |
| - | | |
| 417 | |
| Other non-current assets | |
| 18 | | |
| 113 | |
| Total assets | |
$ | 147,416 | | |
$ | 35,779 | |
| | |
| | | |
| | |
| Liabilities, Non-voting Redeemable Convertible Preferred Stock and Stockholders’ Equity | |
| | | |
| | |
| Current liabilities: | |
| | | |
| | |
| Accounts payable | |
$ | 3,759 | | |
$ | 6,220 | |
| Operating lease liabilities | |
| 69 | | |
| 1,235 | |
| Accrued expenses and other current liabilities | |
| 10,084 | | |
| 5,745 | |
| Total current liabilities | |
| 13,912 | | |
| 13,200 | |
| Warrant liability | |
| 3,784 | | |
| 16,164 | |
| CVR liability | |
| 1,900 | | |
| - | |
| Other non-current liabilities | |
| 1,298 | | |
| 2,264 | |
| Total liabilities | |
| 20,894 | | |
| 31,628 | |
| | |
| | | |
| | |
| Commitments and contingencies | |
| | | |
| | |
| Non-voting redeemable convertible preferred stock | |
| 263,502 | | |
| - | |
| Options for non-voting redeemable convertible preferred stock | |
| 3,267 | | |
| - | |
| Stockholders’ equity | |
| | | |
| | |
| Preferred stock | |
| - | | |
| - | |
| Common stock | |
| 3 | | |
| 3 | |
| Additional paid-in capital | |
| 324,809 | | |
| 320,818 | |
| Accumulated deficit | |
| (465,059 | ) | |
| (316,670 | ) |
| Total stockholders’ equity | |
| (140,247 | ) | |
| 4,151 | |
| Total liabilities, non-voting redeemable convertible preferred stock and stockholders’ equity | |
$ | 147,416 | | |
$ | 35,779 | |